Abstract:Drug discovery starts with known function, either of a compound or a protein, in-turn prompting investigations to probe 3D structure of the compound-protein interface. As protein structure determines function, we hypothesized that unique 3D structural motifs represent primary information denoting unique function that can drive discovery of novel agents. Using a physics-based protein structure analysis platform developed by us, designed to conduct computationally intensive analysis at supercomputing speeds, we probed a high-resolution protein x-ray crystallographic library developed by us. We selected 3D structural motifs whose function was not otherwise established, that offered environments supporting binding of drug-like chemicals and were present on proteins that were not established therapeutic targets. For each of eight potential binding pockets on six different proteins we accessed a 60 million compound library and used our analysis platform to evaluate binding. Using eight-day colony formation assays acquired compounds were screened for efficacy against human breast, prostate, colon and lung cancer cells and toxicity against human bone marrow stem cells. Compounds selectively inhibiting cancer growth segregated to two pockets on separate proteins. The compound, Dxr2-017, exhibited selective activity against human melanoma cells in the NCI-60 cell line screen, had an IC50 of 19 nM against human melanoma M14 cells in our eight-day assay, while over 2100-fold higher concentrations inhibited stem cells by less than 30%. We show that Dxr2-017 induces anoikis, a unique form of programmed cell death in need of targeted therapeutics. The predicted target protein for Dxr2-017 is expressed in bacteria, not in humans. This supports our strategy of focusing on unique 3D structural motifs. It is known that functionally important 3D structures are evolutionarily conserved. Here we demonstrate proof-of-concept that protein structure represents high value primary data to support discovery of novel therapeutics. This approach is widely applicable.

Rethinking Protein Drug Design with Highly Accurate Structure Prediction of Anti-CRISPR Proteins

AI-Based Protein Structure Prediction in Drug Discovery: Impacts and Challenges

Structure Prediction and Computational Protein Design for Efficient Biocatalysts and Bioactive Proteins

De novo design of potent CRISPR-Cas13 inhibitors

Computational design of anti-CRISPR proteins with improved inhibition potency and expanded specificity

Revolutionizing Molecular Design for Innovative Therapeutic Applications through Artificial Intelligence

Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins

Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage

Prediction of protein–protein interactions between anti-CRISPR and CRISPR-Cas using machine learning technique

Accurate positioning of functional residues with robotics-inspired computational protein design

Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors by Cell-Based High-Throughput Screening.

In silico evolution of protein binders with deep learning models for structure prediction and sequence design

Protein Design Using Structure-Prediction Networks: AlphaFold and RoseTTAFold as Protein Structure Foundation Models

Machine-learning approach expands the repertoire of anti-CRISPR protein families

Identifying well-folded de novo proteins in the new era of accurate structure prediction

AcrNET: Predicting anti-CRISPR with Deep Learning

Protein Structure Inspired Drug Discovery

PreAcrs: a Machine Learning Framework for Identifying Anti-Crispr Proteins

PaCRISPR: a server for predicting and visualizing anti-CRISPR proteins

In Silico Approaches for Prediction of Anti-CRISPR Proteins

Effective High-Accuracy Prediction of Protein Structures from Easily Obtainable Artificial Homologous Sequences by Structure-Stability-Based Selection